The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...

The global car-t cell therapy market was valued at USD 5.2 billion in 2024 and is projected to reach USD 26.2 billion by 2030, expected to grow at a CAGR of 31 % during the forecast period, 2025-2030.

Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...

Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash ...